{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T02:23:14Z","timestamp":1787365394962,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37 CA262557"],"award-info":[{"award-number":["R37 CA262557"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA294042"],"award-info":[{"award-number":["R21 CA294042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      This study aimed to retrospectively characterize patients with biochemical failure and peritoneal metastases detected by PSMA PET\/CT, describe the detectability of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT and conventional imaging; and assess patient outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We searched an institutional database for patients who underwent\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 or\n                      <jats:sup>18<\/jats:sup>\n                      \u00a0F-DCFPyL PET\/CT between 5\/2016 and 9\/2024 and measured the SUVmax of the most avid peritoneal lesion. We assessed correlative CT, MRI, or FDG PET\/CT performed within 90 days and validated peritoneal metastases via composite reference. Survival was estimated with Kaplan-Meier analysis. Seven patients subsequently treated with\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 were analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 9,877 screened patients, peritoneal metastases were confirmed in 57. Most had Gleason\u2009\u2265\u20094\u2009+\u20093 (81%) and median PSA was 10.0 ng\/ml (range 0.34\u20131,304); 54% were castration-sensitive. Isolated peritoneal disease occurred in 19 (33%). The median SUVmax was 8.2. Among 29 patients with correlative CT\/MRI, 41% were negative. Of 14 patients with correlative FDG PET\/CT; 43% demonstrated FDG-avid peritoneal disease. On follow-up (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200942), peritoneal disease improved in 38%. Of those with isolated peritoneal metastases and follow-up data (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912), 58% improved. Median overall survival from detection was 53 months (95% CI: 29\u2013not reached), and associated with lower PSA, fewer peritoneal lesions, and non-castration resistance. All seven patients treated with\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 progressed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Peritoneal metastases from prostate cancer are rare. Nevertheless, PSMA-avid peritoneal lesions may represent metastatic spread from prostate cancer, even in the absence of systemic disease. FDG PET\/CT and CT\/MRI often miss peritoneal metastases. Peritoneal disease does not necessarily indicate poor prognosis, particularly when isolated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07703-3","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:40:39Z","timestamp":1765413639000},"page":"3552-3561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shining the PSMA spotlight on peritoneal metastases in prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3458-9904","authenticated-orcid":false,"given":"Jonathan","family":"Kuten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chahwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-6093","authenticated-orcid":false,"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-4185","authenticated-orcid":false,"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-4531","authenticated-orcid":false,"given":"Simone","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"7703_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","DOI":"10.3322\/caac.21820"},{"key":"7703_CR2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Sch\u00f6pfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578\u201383. https:\/\/doi.org\/10.1053\/hp.2000.6698.","journal-title":"Hum Pathol"},{"key":"7703_CR3","first-page":"1083","volume":"78","author":"F Lamothe","year":"1986","unstructured":"Lamothe F, Kovi J, Heshmat MY, Green EJ. Dissemination of prostatic carcinoma: an autopsy study. J Natl Med Assoc. 1986;78:1083\u20136.","journal-title":"J Natl Med Assoc"},{"key":"7703_CR4","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1097\/rlu.0000000000001619","volume":"42","author":"R Ladwa","year":"2017","unstructured":"Ladwa R, Gustafson S, McCaffrey E, Miles K, O\u2019Byrne K. A rare case of omentum invasive prostate cancer: staging with PSMA PET\/CT imaging and response to systemic therapy. Clin Nucl Med. 2017;42:e311\u20132. https:\/\/doi.org\/10.1097\/rlu.0000000000001619.","journal-title":"Clin Nucl Med"},{"key":"7703_CR5","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1097\/rlu.0000000000003414","volume":"46","author":"S Hober\u00fcck","year":"2021","unstructured":"Hober\u00fcck S, Sommer U, Grey A, H\u00f6lscher T, Baretton GB, Kotzerke J. Rapidly evolving diffuse omental carcinomatosis of prostate cancer in 68Ga-PSMA PET\/CT. Clin Nucl Med. 2021;46:e216\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000003414.","journal-title":"Clin Nucl Med"},{"key":"7703_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2022.04.002","volume":"167","author":"SB Goldenthal","year":"2022","unstructured":"Goldenthal SB, Reimers MA, Singhal U, Farha M, Mehra R, Piert M, et al. Prostate cancer with peritoneal carcinomatosis: A Robotic-assisted radical Prostatectomy-based case series. Urology. 2022;167:171\u20138. https:\/\/doi.org\/10.1016\/j.urology.2022.04.002.","journal-title":"Urology"},{"key":"7703_CR7","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1159\/000255336","volume":"32","author":"F Zagouri","year":"2009","unstructured":"Zagouri F, Papaefthimiou M, Chalazonitis AN, Antoniou N, Dimopoulos MA, Bamias A. Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease. Onkologie. 2009;32:758\u201361. https:\/\/doi.org\/10.1159\/000255336.","journal-title":"Onkologie"},{"key":"7703_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/rlu.0000000000004577","volume":"48","author":"LW van Golen","year":"2023","unstructured":"van Golen LW, Seijkens TTP, de Feijter JM, Vogel W. Peritoneal metastases from prostate carcinoma treated with 177 Lu-PSMA-I&T. Clin Nucl Med. 2023;48:422\u20135. https:\/\/doi.org\/10.1097\/rlu.0000000000004577.","journal-title":"Clin Nucl Med"},{"key":"7703_CR9","doi-asserted-by":"publisher","first-page":"e220174","DOI":"10.1148\/rycan.220174","volume":"5","author":"R Woodruff","year":"2023","unstructured":"Woodruff R, Henry C, Scherer P. Peritoneal carcinomatosis of prostate cancer with PSMA-targeted (18)F-DCFPyL PET\/CT. Radiol Imaging Cancer. 2023;5:e220174. https:\/\/doi.org\/10.1148\/rycan.220174.","journal-title":"Radiol Imaging Cancer"},{"key":"7703_CR10","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/rlu.0000000000004734","volume":"48","author":"KS Lau","year":"2023","unstructured":"Lau KS, Le K, Bui C, Wong VCK, Mansberg R. Peritoneal carcinomatosis from metastatic prostate cancer identified on 68 Ga-Prostate-Specific membrane antigen PET\/CT. Clin Nucl Med. 2023;48:704\u20136. https:\/\/doi.org\/10.1097\/rlu.0000000000004734.","journal-title":"Clin Nucl Med"},{"key":"7703_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.urology.2021.05.026","volume":"155","author":"MC King","year":"2021","unstructured":"King MC, Sardi A, Velez-Mejia C, Sittig M, Ledakis P. Novel case of isolated peritoneal carcinomatosis from metastatic prostate cancer carrying a pathogenic BRCA mutation treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Urology. 2021;155:210\u20133. https:\/\/doi.org\/10.1016\/j.urology.2021.05.026.","journal-title":"Urology"},{"key":"7703_CR12","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.3390\/curroncol29070351","volume":"29","author":"HR Jang","year":"2022","unstructured":"Jang HR, Lee K, Lim KH. Isolated peritoneal metastasis of prostate cancer presenting with massive ascites: A case report. Curr Oncol. 2022;29:4423\u20137. https:\/\/doi.org\/10.3390\/curroncol29070351.","journal-title":"Curr Oncol"},{"key":"7703_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eucr.2016.10.004","volume":"10","author":"J Sheng","year":"2017","unstructured":"Sheng J, Findley TW, Sadeghi-Nejad H. Isolated Non-ascitic peritoneal carcinomatosis from metastatic prostate cancer. Urol Case Rep. 2017;10:14\u20135. https:\/\/doi.org\/10.1016\/j.eucr.2016.10.004.","journal-title":"Urol Case Rep"},{"key":"7703_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4103\/0970-1591.65405","volume":"26","author":"SP Benedict","year":"2010","unstructured":"Benedict SP, Ahuja M, Mammen KJ. Hormone refractory carcinoma prostate with peritoneal metastases and malignant Ascites without skeletal involvement: A case report and review of literature. Indian J Urol. 2010;26:287\u20138. https:\/\/doi.org\/10.4103\/0970-1591.65405.","journal-title":"Indian J Urol"},{"key":"7703_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/rlu.0000000000002843","volume":"45","author":"DH Simsek","year":"2020","unstructured":"Simsek DH, Sanli Y. Detection of unusual peritoneal metastases of prostate cancer with 68Ga-Prostate-Specific membrane antigen PET\/CT. Clin Nucl Med. 2020;45:63\u20134. https:\/\/doi.org\/10.1097\/rlu.0000000000002843.","journal-title":"Clin Nucl Med"},{"key":"7703_CR16","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1097\/rlu.0000000000003802","volume":"47","author":"X Ji","year":"2022","unstructured":"Ji X, Wang L, Lin J, Tang K. Detection of diffuse peritoneal and omental metastases from prostate cancer with 18F-PSMA-1007 PET\/CT. Clin Nucl Med. 2022;47:e74\u20136. https:\/\/doi.org\/10.1097\/rlu.0000000000003802.","journal-title":"Clin Nucl Med"},{"key":"7703_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/rlu.0000000000004805","volume":"48","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Dong A, Zuo C. 68Ga-PSMA-11 PET\/CT in a case of isolated parietal peritoneal metastasis from prostate adenocarcinoma. Clin Nucl Med. 2023;48:913\u20134. https:\/\/doi.org\/10.1097\/rlu.0000000000004805.","journal-title":"Clin Nucl Med"},{"key":"7703_CR18","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1097\/rlu.0000000000001703","volume":"42","author":"B Kranzb\u00fchler","year":"2017","unstructured":"Kranzb\u00fchler B, Tran S, Zilli T, Burger IA. 68Ga-PSMA PET\/MR-Positive peritoneal metastasis in the falciform ligament in recurrent prostate cancer. Clin Nucl Med. 2017;42:e388\u20139. https:\/\/doi.org\/10.1097\/rlu.0000000000001703.","journal-title":"Clin Nucl Med"},{"key":"7703_CR19","doi-asserted-by":"publisher","first-page":"Fso707","DOI":"10.2144\/fsoa-2021-0009","volume":"7","author":"E Delchambre","year":"2021","unstructured":"Delchambre E, Rysselinck S, Pairet G, Confente C, Seront E. Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature. Future Sci OA. 2021;7:Fso707. https:\/\/doi.org\/10.2144\/fsoa-2021-0009.","journal-title":"Future Sci OA"},{"key":"7703_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of Intermediate- to High-risk prostate cancer: A systematic review and Meta-analysis. Eur Urol. 2023;84:36\u201348. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.001.","journal-title":"Eur Urol"},{"key":"7703_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1967\/s002449912219","volume":"23","author":"M Gupta","year":"2020","unstructured":"Gupta M, Karthikeyan G, Choudhury PS, Sharma A, Singh A, Rawal S. Is (177)Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis? Hell J Nucl Med. 2020;23:312\u201320. https:\/\/doi.org\/10.1967\/s002449912219.","journal-title":"Hell J Nucl Med"},{"key":"7703_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/rlu.0000000000003307","volume":"45","author":"S Satapathy","year":"2020","unstructured":"Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of Castration-Resistant prostate cancer treated with 177Lu-Labeled prostate-Specific membrane antigen radioligand therapy: A systematic review and Meta-analysis. Clin Nucl Med. 2020;45:935\u201342. https:\/\/doi.org\/10.1097\/rlu.0000000000003307.","journal-title":"Clin Nucl Med"},{"key":"7703_CR23","first-page":"974","volume":"28","author":"CG Drake","year":"2014","unstructured":"Drake CG. Visceral metastases and prostate cancer treatment: \u2018die hard,\u2019 \u2018tough neighborhoods,\u2019 or \u2018evil humors\u2019? Oncology. (Williston Park). 2014;28:974\u201380.","journal-title":"(Williston Park)"},{"key":"7703_CR24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/s0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"7703_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.radcr.2022.10.024","volume":"18","author":"J K\u00fchl","year":"2023","unstructured":"K\u00fchl J, Buch-Olsen KM, Elhakim MT. Prostate cancer metastasis mimicking appendicitis-A rare but important differential diagnosis in PET\/CT imaging. Radiol Case Rep. 2023;18:266\u201370. https:\/\/doi.org\/10.1016\/j.radcr.2022.10.024.","journal-title":"Radiol Case Rep"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07703-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T01:32:24Z","timestamp":1787362344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07703-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7703"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07703-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was performed under an institutional IRB.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that, where applicable, data was anonymized to protect participant privacy, and consent to publish was not deemed necessary.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}